Table 1.

Trial characteristics of CPP therapies (approved in US) in pivotal trials.

Drug name	Duration of action (months)	Dose (mg)	Years of study	Individual patient trial duration (months)	Number of patients
LUPRON DEPOT-PED (13, 22–24)	1	7.5	1991–2009	48	55
	3	11.25, 30	2008–2010	6	84
TRIPTODUR (15)	6	22.5	2012–2014	12	44
FENSOLVI (16)	6	45	2015–2018	12	64
SUPPRELIN (17, 25)	12	50	2004–2012	12	36

Pivotal trials for CPP therapies were conducted during different decades and had varying durations.

CPP, central precocious puberty; NR, not reported.